drugset
drugset / Trial / NCT00384917

Study to Determine the Impact of Multiple Doses of Ketoconazole on Single-Dose Pharmacokinetics of HCV-796

NCT00384917 ↗

Phase 1 Completed 24 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
Non-randomizedSingle-groupOpen-labelTreatment

Summary

An open label, 2-period, sequential study to determine the impact of multiple doses of ketoconazole on single-dose pharmacokinetics of HCV-796

Timeline

Start
2006-08
Primary completion
—
Completion
2006-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Ketoconazole Small molecule — —

Indications

No indication recorded.